Galux Unveils a Study in AI-Powered De Novo Antibody Design for Multiple Therapeutic Targets
SEOUL, South Korea — March 17, 2025 — Galux Inc., a South Korean startup specializing in AI-driven protein therapeutics design, has published a study showcasing the capabilities of its AI…